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While the majority of myelodysplasia and acute myeloid
leukemia (MDS/AML) cases are sporadic, rare familial
predisposition syndromes have been delineated and now
represent a separate disease entity in the revised World
Health Organization (WHO) classification of myeloid neo-
plasms [1]. Germline mutations in ~14 disease genes have
been uncovered thus far, with GATA2 representing one of
the key transcriptional regulators commonly mutated in
inherited MDS/AML [2]. Increasing evidence suggests that
aberrations in GATA2 impair its transcription and promoter
activation, leading to a loss-of-function, supporting a
mechanism of GATA2 haploinsufficiency [3–5]. Reduced
penetrance, the observation that family members carry an
identical germline mutation yet display variable clinical
manifestations, is common and poses a clinical challenge in
the diagnosis and management of familial leukemia's, par-
ticularly when identifying “silent” mutation carriers for
genetic screening and exclusion as potential stem cell
transplant donors [6, 7]. Indeed, we have noted that reduced
penetrance is a feature among certain GATA2-mutated
MDS/AML families [8], especially those harboring mis-
sense germline mutations such as c.1061C>T (p.
Thr354Met) (Table S1) although the precise molecular
explanation of such occurrence has not been investigated.
Analysis of five MDS/AML families harboring p.
Thr354Met GATA2 mutations displayed significant intra-
and interfamilial variations in disease latency, phenotype,
and penetrance (Figure S1). These observations suggest that
individuals require additional co-operating events for the
development of overt malignancy within the context of a
shared germline mutation. To investigate this hypothesis
further, we examined an extensive five-generation pedigree
[9] (Fig. 1a) where two first-degree cousins (IV.1 and IV.6)
developed high-risk MDS/AML with monosomy 7, while a
third cousin (IV.10) presented with recurrent minor infec-
tions and significant monocytopenia [0.1 × 109/L] and
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neutropenia [0.8 × 109/L] in year (yr.) 1–3 which subse-
quently stabilized (monocyte count, neutrophils [>1 × 109/
L]) 3 years after presentation (Fig. 1b). This contrasted with
the parental generation (III.1, III.5, and III.7) where muta-
tion carriers remain symptom-free with no evidence of
hematopoietic abnormality over 60 years of age.
A. F. Al Seraihi et al.
We therefore started with targeted deep sequencing of 33
genes frequently mutated in MDS/AML to define the
landscape of secondary genetic mutations across mutation
carriers. Notably, while no acquired mutations were detec-
ted in asymptomatic family members, all affected cousins
analyzed shared an identical somatic ASXL1 mutation (p.
Gly646TrpfsTer12) (Fig. 1c). The variant allele frequency
(VAF), however, was lower (12%) in IV.10 and remained
stable (range 12–6%) over a 6-year monitoring period.
While the co-occurrence of ASXL1 and GATA2 mutations
has been proposed as one mechanism for driving the onset
and severity of disease symptoms [9–11], the low VAF of
ASXL1 mutation and stable improvement in hematopoiesis
at IV.10 later follow-up suggested that a combination of
GATA2–ASXL1 mutation alone is insufficient to promote
clonal expansion and leukemic transformation, as this sec-
ondary somatic hit may not represent disease progression or
identify when treatment is indicated. Intriguingly, apart
from the ASXL1 mutation, no other acquired mutations were
detected in the 33-myeloid genes assessed in the affected
individuals. Moreover, on the basis of our observations and
in agreement with previous studies [12, 13], it seems that
monosomy 7 in IV.1 and IV.6 is acquired following
acquisition of ASXL1 mutations, hence contributing to the
malignancy but not initiating symptoms.
We next considered whether disease symptoms are
modulated by endogenous levels of GATA2. Quantitative
real-time PCR (qRT-PCR) of bone marrow material
demonstrated total GATA2 expression to be significantly
lower in the symptomatic (IV.10-yr.1) compared with an
asymptomatic carrier (III.7) (Fig. 1d). Significantly, Sanger
sequencing of the cDNA template revealed striking allele-
specific expression (ASE), favoring the mutant (T) allele
with the absence of the wild-type (WT) (C) allele expres-
sion in the symptomatic patient (IV.10), contrasting with
biallelic expression in asymptomatic members (III.5 and
III.7) (Fig. 1e). This observation was validated by cDNA
cloning of III.7 and IV.10 bone marrow samples and sub-
sequent Sanger sequencing of individual clones (Figure S2).
As this suggested that an allelic imbalance in WT:mutant
GATA2 expression ratio may account for the variable dis-
ease penetrance in this pedigree, we assessed GATA2
expression in IV.10 over a 6-year disease period at four
time-points (yr. 1, 3, 4, and 6), demonstrating increased
GATA2 expression at later time-points (yr. 4 and 6)
(Fig. 1d) coinciding with reactivation of the WT (C) allele
expression (Fig. 1f) and an improvement in hematological
parameters, in the absence of any clinical intervention
(Fig. 1b).
To test whether monoallelic GATA2 expression has an
impact on the transcriptome driving the onset of disease
symptoms, we performed RNA-seq with a view of exam-
ining downstream biological features distinctive of GATA2
monoallelic (IV.10-yr.1 and 3) vs. biallelic (IV.10-yr.4 and
III.7) groups. Unsupervised analysis revealed a clear
separation between GATA2 monoallelic and biallelic sam-
ples (Fig. 1g, S3 and Table S2). It was noteworthy that
certain canonical pathways and gene sets related to tumor-
igenesis (e.g., DNA replication and cell cycle) were enri-
ched in GATA2 monoallelic vs. biallelic groups (Figure S4),
potentially reflecting the clinical and phenotypic switch
Fig. 1 Investigating the molecular mechanisms underlying the reduced
penetrance of germline p.Thr354Met mutations observed in a GATA2-
mutated MDS/AML family. a Genogram of the GATA2-mutated
pedigree. Squares denote males and circles denote females. This five-
generation MDS/AML family presented to Barts Health hospital in
London with identical germline GATA2 mutations (p.Thr354Met;
c.1061C>T) and variable clinical manifestations. Two first-degree
cousins (IV.1 and IV.6) presented at 23 and 18 years of age, respec-
tively, with high-grade MDS transforming to AML and monosomy 7.
Both cousins died post allogeneic hematopoietic stem cell transplant
(HSCT) due to transplant-related complications (IV.1 from graft vs.
host disease (GvHD) and IV.6 from relapsed MDS/AML). Ten years
later, their first cousin (IV.10) developed symptoms at 31 years,
including recurrent minor infections and significant leukopenia
(monocytopenia [0.1 × 109/L] and neutropenia [0.8 × 109/L]) with mild
macrocytosis and normal hemoglobin and platelet counts. She remains
under close surveillance where her blood counts are routinely mon-
itored. All four of her children have inherited her WT GATA2 allele.
Similarly, members (IV.7, IV.8, and IV.9) were screened for the
mutation and all have a WT GATA2 configuration. The paternal
grandmother (II.2) of IV.10 as well as her paternal great-uncle (II.3)
and great-grandmother (I.2) all were reported to have died of AML
(ages of disease onset were 53, 24, and 53-years old, respectively). Not
only did GATA2 mutations correlate with early age of disease onset in
the fourth generation (IV.1/23 yr., IV.6/18 yr., and IV.10/31 yr.), but
the parental third-generation carriers (III.1, III.5, and III.7) remain
hematologically normal and symptom-free into their mid–late 60s. No
material was available from other family members. b A clinical
timeline of IV.10 showing the change in clinical parameters over the
course of disease presentation. Photographs of peripheral blood smears
from IV.10 (yr. 1, 3, 4, and 6) stained with May-Grünwald Giemsa
staining. Magnification: ×20. c Secondary ASXL1 mutations: variant
allele frequencies of GATA2 germline mutation and ASXL1 acquired
mutation. Samples from three individuals were sequenced: one
asymptomatic parent (III.7), one deceased MDS/AML cousin (IV.6),
and across three time-points (yr. 1, 4, and 6) from the symptomatic
patient (IV.10) reflecting disease evolution. d GATA2 global expres-
sion measured by qRT-PCR of bone marrow samples and normalized
to healthy bone marrow control: downregulation in IV.10_yr.1 com-
pared with III.7 and downregulation in IV.10_yr.1–3 GATA2 expres-
sion compared with IV.10_yr.4–6. The average of five independent
experiments is shown. Statistical significance was determined at *p <
0.05, **p < 0.01, and ***p < 0.001 using a t-test with Bonferroni
correction. Error bars represent standard error of the mean (SEM). e
GATA2 monoallelic expression of the mutant allele in symptomatic
(IV.10) vs. asymptomatic carriers (III.5 and III.7), as measured by
cDNA sequencing of bone marrow samples. f Correlation of mono-
allelic GATA2 expression with disease symptoms across the time-
points studied in IV.10 with reactivation of the WT allele “C”
expression noted 3 years after presentation, concurrent with
improvements in hematological parameters. g RNA-seq analysis:
principal component analysis (PCA) plot showing a good separation
between GATA2 biallelic (green) and monoallelic (blue) groups based
on all transcriptomes
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Fig. 2 Elucidating the molecular mechanisms driving allele-specific
changes in GATA2 expression. a(i) A noncoding SNP (rs1806462 [C/
A]) located within the second GATA2 promoter region overlapping a
CpG island was detected in the symptomatic (IV.10) but not in
asymptomatic members (III.7). a(ii) Given the location of promoter 2
SNP within the 5’UTR, a haplotype between the SNP allele “A” and
the germline mutant allele “T” was established, providing a means of
distinguishing between mutant and WT alleles in subsequent experi-
ments. a(iii) This promoter SNP [C/A] removes a CpG methylation
site in the mutant allele “A” and generates a CpG methylation site in
the WT allele “C”. b The proportion of methylated CpGs between
mutant and WT alleles across the three time-points of IV.10. WT allele
is significantly more methylated than the mutant allele in monoallelic
samples (yr. 1 and yr. 3), whereas no significant allele-specific dif-
ferences in methylation were observed in a biallelic-expressing sample
(yr. 6). The average of three independent experiments is shown. c
Quantification of mutant and WT allele ChIP sequence peak heights
across the time-points of IV.10 based on Sanger sequencing.
H3K4me3 activation mark favoring the mutant allele was enriched in
monoallelic samples (yr. 1 and yr. 3) compared with the biallelic
sample (yr. 4). The average of three independent experiments is
shown. Statistical significance was determined at *p < 0.05, **p <
0.01, and ***p < 0.001 using a t-test with Bonferroni correction. NS
corresponds to nonsignificant comparisons. Error bars represent SEM
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between these two groups. We also noted a significant
overexpression of genes with GATA2 cofactor PU.1 motifs
in their regulatory regions (p value NES= 2.06) in GATA2
biallelic vs. monoallelic samples, in support of a recent
finding [14] that p.Thr354Met mutants bind and interact
with PU.1 more tightly than WT, thus leading to seques-
tration of PU.1 from its normal cellular functions. Conse-
quently, the transcriptional activation triggered by PU.1 will
be diminished in our GATA2 monoallelic samples.
The differences observed in these gene-expression pro-
files prompted us to explore the molecular mechanisms
underlying monoallelic GATA2 expression. We hypothe-
sized that these allele-specific changes in GATA2 expression
are driven by transient epigenetic mechanisms that include
changes in DNA methylation and chromatin mark deposi-
tion. A CpG single-nucleotide polymorphism (CpG-SNP)
(rs1806462) [C/A] located within the promoter and 5′UTR
of GATA2 overlapping a CpG island offered a marker to
distinguish between mutant and WT alleles where this SNP
creates/abolishes a CpG dinucleotide within the GATA2
promoter region (Fig. 2a). More specifically, cDNA
sequencing of 5′UTR allowed us to define haplotypes,
where the promoter SNP allele (A) resides on the germline
mutant GATA2 allele (T) (Fig. 2a(ii)). Apart from IV.10, no
other family members and only 2/12 individuals from
pedigrees presented in Figure S1 were heterozygous for this
SNP (one of whom is an asymptomatic carrier). Therefore,
we do not infer that this haplotype would contribute to the
progression of symptoms. Instead, we used this SNP to
determine whether allele-specific differences in DNA
methylation could explain the silencing of WT GATA2
allele expression observed in earlier time-points of IV.10.
As illustrated in Fig. 2b and S5, bisulfite sequencing of a
200-bp region encompassing rs1806462 demonstrated a
significant increase in promoter methylation in the WT
allele of IV.10 in yr. 1 and yr. 3 following diagnosis, in
contrast with the absence of allele-specific differences in
methylation at a later time-point.
We next sought to establish whether these allele-specific
changes in GATA2 methylation and expression are accom-
panied by changes in chromatin structure at the promoter.
H3K4me3 and H3K27me3 define poised or closed chro-
matin, respectively, rendering them more or less accessible
for transcription factors, thereby regulating gene expression
[15]. The deposition of these bivalent marks was assessed in
IV.10 by allele-specific chromatin immunoprecipitation
(ChIP) followed by Sanger sequencing within GATA2
promoter region encompassing the SNP rs1806462 [C/A].
While there were no apparent allele-specific differences in
H3K27me3 deposition across the different time-points of
IV.10, an enrichment in the deposition of H3K4me3 on the
promoter of the mutant allele (A) relative to the WT allele
(C) was noted in IV.10 monoallelic samples (yr. 1 and 3)
(Fig. 2c, S6 and S7). In contrast, and consistent with the
pattern observed with DNA methylation, there was no
demonstrable difference in H3K4me3 deposition in the
IV.10 biallelic sample (yr. 4), coinciding with reactivation
of the WT allele expression and an overall improvement in
clinical parameters. We believe that these observations are
in keeping with the notion that H3K4me3 occupancy inhi-
bits de novo DNA methylation [16] which was borne out by
subsequent bisulfite sequencing of H3K4me3-enriched
DNA from our ChIP experiments, demonstrating that
DNA methylation and H3K4me3 deposition are mutually
exclusive in our IV.10 samples (Figure S8).
Collectively, our findings provide a step forward in
understanding the molecular mechanisms underlying
reduced penetrance in GATA2-mutated MDS/AML pedi-
grees, which may be governed by the acquisition of addi-
tional co-operating mutations (e.g., ASXL1) combined with
dynamic epigenetic reprogramming and subsequent allele-
specific expression of GATA2 mutant allele, adding another
level of complexity to the (epi)genetic basis of familial
MDS/AML.
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